ENAapplication/xmlftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR231/015/SRR23152615/SRR23152615.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR231/017/SRR23152617/SRR23152617.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR231/018/SRR23152618/SRR23152618.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR231/016/SRR23152616/SRR23152616.fastq.gzprimaryOK200GenomicsMoffitt Cancer Centerhttps://www.ebi.ac.uk/ena/browser/view/PRJNA925849Mus musculusTowards the goal of developing new therapeutic modalities, we investigated the impact of individual and combined activation of CD40 and type 1 IFN pathways on mouse tumor cDCs. To this end, we utilized replication-deficient adenoviruses expressing a membrane-stable CD40L (MEM40), mouse IFNb (mIFNB) and a control null virus (Ad-Null). Then We used single cell RNA sequencing (scRNA-seq) to analyze the gene expression profile in the advs treated tumors of DCs . Overall design: C57BL/6 mice were inoculated s.c. with 5*e5 B16-F10 cells. On D12, mice were subjected to an intratumoral injection with adenoviruses (Advs). Each scRNA-seq sample was pooled from 3 different similarly treated tumors, CD11c+ MHC-II+ sorted cells were used for 10x Genomics scRNAseq.ENAfalseGene expression profile at single cell level of DC from B16F10 tumor with Advs treatmentGene expression profile at single cell level of DC from B16F10 tumor with Advs treatment2025-09-242023-02-15PRJNA925849GSE22334410090